Protein Predicts Response To New Immunotherapy Drug
News Nov 28, 2014
The presence of an immune-suppressing protein in non-cancerous immune cells may predict how patients with different types of cancer respond to treatment, a multi-center phase I study using an investigational immune therapy drug has found.
The study, led by a Yale Cancer Center investigator, is described in the Nov. 27 edition of the journal Nature.
The trial included patients with melanoma or cancers of the lung, kidney, colon, GI tract, or head and neck, whose tumors were evaluated for PD-L1 expression by a novel assay. PD-L1 is a protein expressed by many tumor types that is believed to act as a stop sign that prevents the immune system from attacking cancer cells. Patients were treated with MPDL3280A, a drug that blocks PD-L1 and is being developed by Genentech, a member of the Roche group.
The trial differed from other immune therapy trials in that it incorporated serial biopsies of patients before and during treatment to identify a tumor profile that predicts response to treatment, said the paper’s first author, Roy Herbst, Ensign Professor of Medicine at Yale Cancer Center, professor of pharmacology, and chief of medical oncology in Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven.
“We knew that the expression of PD-L1 in tumor cells is critical in blocking the immune system so we were intrigued to find that the expression of PD-L1 in non-tumor cells such as macrophages also predicted drug response,” said Herbst.
The serial biopsies revealed the characteristics of both functional and non-functional immune responses and provided a baseline for how patients respond and don’t respond to treatment.
“We can begin learning how to use combination therapies to affect the immune response cycle,” Herbst said.
Of the 175 patients enrolled, 21% showed partial or complete response to MPDL3280A, with some being rapid and durable. Across all tumor types, 46% of patients with high PD-L1 expression on non-tumor cells showed a partial or complete response. Also notable was the finding that smokers responded better to the drug than non-smokers. This could provide insight into how smokers and nonsmokers respond differently to drugs, said the researchers.
Herbst said the drug is in phase II and III trials at Yale.
Also published in the same issue of Nature are additional findings from this same trial, including the response of advanced bladder cancer patients who did not respond to other treatments. This expansion arm study was co-authored by Thomas Powles of Queen Mary University Hospital of London with Daniel P. Petrylak, professor of medicine and urology at Yale Cancer Center, and Joseph Paul Eder, professor of medicine at Yale Cancer Center. Petrylak presented the findings earlier this year at ASCO’s annual conference.
“It is encouraging that a trial that began in lung, melanoma, and renal cancer expanded to bladder cancer, another smoking-related cancer, with such promising results,” Herbst added.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.